Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Arix Bioscience plc
  6. News
  7. Summary
    ARIX   GB00BD045071

ARIX BIOSCIENCE PLC

(ARIX)
  Report
Delayed Quote. Delayed London Stock Exchange - 07/23 11:35:19 am
176.5 GBX   --.--%
12:06pTransaction in own shares
DJ
07/21Notice of Results
DJ
07/19Transaction in own shares
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Change of registered office

05/20/2021 | 02:01am EDT
Arix Bioscience PLC (ARIX) 
Change of registered office 
20-May-2021 / 07:00 GMT/BST 
Dissemination of a Regulatory Announcement, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
Arix Bioscience plc 
 
Change of registered office 
 
LONDON, 20 May 2021: Arix Bioscience plc ("Arix", LSE: ARIX), a global venture capital company focused on investing in 
and building breakthrough biotech companies, announces that it has changed its registered office to Duke Street House, 
50 Duke Street, London W1K 6JL, with immediate effect. 
 
[ENDS] 
For more information on Arix, please contact: 
 
Arix Bioscience plc 
Charlotte Parry, Head of Investor Relations 
+44 (0)20 7290 1072 
charlotte@arixbioscience.com 
 
Optimum Strategic Communications 
Mary Clark, Supriya Mathur, Shabnam Bashir 
+44 (0)20 3922 1906 
optimum.arix@optimumcomms.com 
 
About Arix Bioscience plc 
Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech 
companies around cutting-edge advances in life sciences. 
 
We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate 
their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth 
phase of our industry to a broader range of investors. www.arixbioscience.com 
 
=---------------------------------------------------------------------------------------------------------------------- 
ISIN:           GB00BD045071 
Category Code:  MSCH 
TIDM:           ARIX 
LEI Code:       213800OVT3AHQCXNIX43 
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State 
Sequence No.:   106190 
EQS News ID:    1198587 
 
End of Announcement  EQS News Service 
=------------------------------------------------------------------------------------
 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1198587&application_name=news 
 

(END) Dow Jones Newswires

May 20, 2021 02:00 ET (06:00 GMT)

Stocks mentioned in the article
ChangeLast1st jan.
ARIX BIOSCIENCE PLC 0.00% 176.5 Delayed Quote.-19.41%
DJ INDUSTRIAL 0.68% 35061.55 Delayed Quote.13.69%
All news about ARIX BIOSCIENCE PLC
12:06pTransaction in own shares
DJ
07/21Notice of Results
DJ
07/19Transaction in own shares
DJ
07/16Transaction in own shares
DJ
07/14Transaction in own shares
DJ
07/12Transaction in own shares
DJ
07/07Transaction in own shares
DJ
07/06ARIX BIOSCIENCE : Appoints New Managing Director
MT
07/06Team changes
DJ
07/01Total Voting Rights
DJ
More news
Financials
Sales 2021 0,50 M 0,69 M 0,69 M
Net income 2021 37,7 M 51,8 M 51,8 M
Net cash 2021 175 M 241 M 241 M
P/E ratio 2021 6,11x
Yield 2021 -
Capitalization 222 M 306 M 305 M
EV / Sales 2021 94,2x
EV / Sales 2022 103x
Nbr of Employees 12
Free-Float 72,3%
Chart ARIX BIOSCIENCE PLC
Duration : Period :
Arix Bioscience plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARIX BIOSCIENCE PLC
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 1,77 GBX
Average target price 221,50 GBX
Spread / Average Target 12 450%
EPS Revisions
Managers and Directors
Robert William Henry Lyne CEO, COO, Secretary, Director & General Counsel
Christian Schetter Managing Director
Marcus Karia Group Finance Director
Peregrine D. E. M. Moncreiffe Non-Executive Chairman
Graeme Smith Chief Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
ARIX BIOSCIENCE PLC-19.41%309
INVESTOR AB (PUBL)43.13%70 889
CK HUTCHISON HOLDINGS LIMITED6.01%30 519
AB INDUSTRIVÄRDEN (PUBL)24.51%16 599
HAL TRUST30.05%14 468
KINNEVIK AB80.07%11 032